GSK1292263(CAS:1032823-75-8)

GSK1292263 (CAS 1032823-75-8) is a new-generation potent oral selective GPR119 agonist independently developed by GlaxoSmithKline. Featuring precise target binding capability, excellent oral bioavailability and clear metabolic regulatory mechanism, it has become a core scientific research API for global metabolic pharmacology laboratories, CRO institutions and pharmaceutical R&D teams. It is widely applied in the analysis of type 2 diabetes pathogenesis, GPR119 receptor structural research, screening of novel glucose and lipid metabolism drugs, and preclinical efficacy evaluation. With stable physical and chemical properties, high purity, ultra-low impurities and excellent batch uniformity, GSK1292263 fully supports full-process scientific research scenarios including in vitro cell experiments, molecular binding mechanism verification, animal model construction and high-throughput compound screening. It is resistant to degradation under long-term low-temperature storage and delivers highly repeatable experimental results, serving as a standard positive control tool compound for GPR119 target research.

In terms of core pharmacological mechanism, GPR119 is a G-protein coupled receptor specifically expressed in intestinal endocrine L cells and pancreatic β-cells, representing a novel metabolic regulatory target independent of DPP4, SGLT2 and FFAR1 and a popular direction for innovative hypoglycemic drug research. GSK1292263 exhibits potent and stable in vitro agonistic activity, with a pEC50 of 6.9 for human GPR119 and 6.7 for rat GPR119. It accurately binds to the transmembrane domain of GPR119, stabilizes the active receptor conformation through hydrophobic interactions and aromatic amino acid binding, and significantly elevates intracellular cAMP levels to activate complete downstream signaling cascades. On the one hand, it efficiently promotes the secretion of incretins such as GLP-1 and GIP from intestinal L cells to amplify glucose-dependent insulin secretion. On the other hand, it inhibits abnormal glucagon release and reduces hepatic glucose output, achieving stable all-day glycemic regulation through dual synergistic mechanisms. Different from sulfonylureas, it only exerts pharmacological effects under hyperglycemia, fundamentally avoiding spontaneous hypoglycemia risks with prominent medication safety advantages.

In scientific research applications, GSK1292263 possesses irreplaceable core research value. Supported by mature cryo-EM crystal structure data, it is commonly used to analyze GPR119 receptor activation mechanisms, ligand binding modes and the functions of key amino acid sites, providing core data support for the structural design and optimization of novel agonist molecular scaffolds. Meanwhile, it is widely deployed in type 2 diabetes pharmacological research, effectively improving insulin resistance, reducing fasting and postprandial blood glucose, and regulating glucose and lipid metabolism disorders in model animals. In addition, it can be combined with classic hypoglycemic drugs such as metformin and sitagliptin for synergistic efficacy experiments, exploring multi-pathway combined glycemic control regimens and providing experimental basis for clinical combined medication and compound preparation development. Beyond hypoglycemic research, it is also applied in basic mechanism studies of obesity and metabolic syndrome with extensive application scenarios.

In terms of raw material supply and industrial research value, GSK1292263 adopts mature synthetic routes and advanced purification technology to accurately remove structurally related impurities with stable qualified purity. Complete supply specifications meet various scientific research demands ranging from milligram-level screening to gram-level animal experiment amplification. With excellent oral activity, convenient animal administration, no obvious liver and kidney toxicity after long-term intervention and a wide safe experimental window, it is suitable for long-term pharmacodynamic and toxicological studies. With the booming global R&D of GPR119-targeted innovative drugs, research institutions continue to optimize lead compound structures, in vivo efficacy and safety, driving sustained growing demand for standardized high-activity positive control tool compounds. Endowed with definite target activity, complete literature data and stable experimental performance, GSK1292263 has become an essential core raw material in metabolic disease research, maintaining long-term stable scientific research value and broad application prospects in the R&D track of innovative drugs for diabetes and metabolic syndrome.